| Name | Title | Contact Details |
|---|
Valiant Living is a company that offers comprehensive outpatient treatment and recovery services for men and their families, as well as enhanced recovery living environments for men who need a productive transition period after primary treatment.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
ConnectYourCare’s comprehensive and flexible consumer-directed health care (CDH) solution provides a fast path to account-based health plans like Health Savings Accounts (HSA), Flexible Spending Accounts (FSA), Health Reimbursement Arrangements (HRA) and other tax-advantaged benefit accounts including COBRA, Transportation and Adoption Assistance. We help businesses lower benefit costs while empowering consumers to achieve health care savings with simple, powerful tools and a robust suite of educational materials. The solution of choice for brokers, employers, health plans and banks, ConnectYourCare’s smartCDH™ technology platform offers a fresh approach to health savings by combining a simplified experience and seamless access. Developed with all tax-advantaged savings accounts in mind, smartCDH works with equal precision across all account types – and those still to come. By removing complexity and motivating individuals to take control of health savings, ConnectYourCare maximizes return on investment for all participants in the health care benefits marketplace.
TSN Labs Inc is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Health One is a Ridgeland, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.